Current Pipeline for Noninfectious Uveitis

Systemic and local treatments being investigated in clinical trials include TYK2/JAK1 modulators and IL-6 inhibitors.

By: Jim Gallagher, senior managing editor

Retinal Physician May 9, 2025

Clinical Report: Current Pipeline for Noninfectious Uveitis

Overview

This report highlights the latest investigational therapies for noninfectious uveitis, including systemic treatments like brepocitinib, a TYK2/JAK1 inhibitor dosed orally once daily, and local therapies such as vamikibart. These therapies are currently in late-stage clinical trials and may significantly enhance treatment options for this condition.

Background

Noninfectious uveitis is a complex group of ocular inflammatory diseases that can lead to vision loss if not effectively managed. The development of new therapies is crucial as current treatments often have significant side effects. Understanding the evolving landscape of treatment options is essential for optimizing patient care.

Data Highlights

Therapy	Type	Phase	Key Findings
Brepocitinib	Systemic	Phase 3	Shows dose-dependent reduction in inflammation
Vamikibart	Local	Phase 3	Favorable safety profile and preliminary efficacy
KSI-101	Local	Phase 1b	Combines IL-6 inhibition with VEGF trap; pivotal studies planned for 2025
TRS01	Topical	Phase 3	Encouraging results in anterior chamber inflammation; ongoing evaluation against prednisolone acetate

Key Findings

Brepocitinib is a promising TYK2/JAK1 inhibitor showing dose-dependent reduction in inflammation.
Vamikibart, an IL-6 inhibitor, is being studied for uveitic macular edema with a favorable safety profile.
KSI-101 combines IL-6 inhibition with VEGF trapping, potentially enhancing treatment durability; pivotal studies planned for 2025.
TRS01 shows promise in treating anterior uveitis without increasing intraocular pressure; ongoing evaluation against prednisolone acetate.
Several therapies, including izokibep and ESK-01, have failed to advance in clinical trials, impacting future treatment strategies.

Clinical Implications

The emergence of new therapies for noninfectious uveitis may provide clinicians with more effective options that minimize side effects associated with traditional treatments. Ongoing clinical trials will help establish the safety and efficacy of these novel agents, potentially changing the standard of care. The failure of several therapies highlights the challenges in developing effective treatments.

Conclusion

The current pipeline for noninfectious uveitis treatments is promising, with several investigational therapies showing potential to improve patient outcomes. Continued research and clinical trials are essential to validate these findings and integrate them into clinical practice.

PentaVision

Retinal Physician